Chemical Stock Surges 19% After Q1 Profit Doubles; Brokerage Sees 8% More Upside

Tatva Chintan Pharma Chem Ltd shares surged nearly 19% during Monday's trading session after the specialty chemicals manufacturer reported a sharp improvement in its financial performance for the first quarter of FY27. The company posted more than a two-fold increase in net profit, supported by 43% revenue growth, stronger operating margins and higher EBITDA, prompting renewed buying interest in the stock.

The quarterly performance was accompanied by the board's approval of a ₹200 crore capacity expansion at its Dahej-III manufacturing facility in Gujarat and the reappointment of its key executive leadership. Following the earnings announcement, Deven Choksey Research reiterated its 'Accumulate' rating on the stock with a target price of ₹1,765, implying further upside from current levels.

The strong set of numbers reflects improving demand across Tatva Chintan Pharma Chem's specialty chemicals portfolio, better operating leverage and continued expansion into high-value chemical segments, including pharmaceutical intermediates, battery chemicals and semiconductor chemicals.

Tatva Chintan Pharma Chem Q1 FY27 Results

Tatva Chintan Pharma Chem reported broad-based growth across its key financial metrics during the June quarter, with revenue and profitability expanding significantly compared with the same period last year.

Q1 FY27 Financial Performance

Particulars	Q1 FY27	Q1 FY26	YoY Growth
Revenue from Operations	₹167 crore	₹116.8 crore	43%
Net Profit	₹16 crore	₹7 crore	More than 100%
EBITDA	₹32.1 crore	₹17.2 crore	86.6%
EBITDA Margin	19.2%	14.7%	+450 bps

Revenue from operations increased 43% year-on-year to ₹167 crore from ₹116.8 crore, while consolidated net profit more than doubled to ₹16 crore from ₹7 crore reported in the corresponding quarter of the previous financial year.

Operating performance also improved sharply, with EBITDA rising 86.6% year-on-year to ₹32.1 crore from ₹17.2 crore. EBITDA margin expanded by 450 basis points to 19.2% from 14.7%, reflecting improved operating efficiencies, better product mix and higher manufacturing utilisation.

Tatva Chintan Share Price Performance

The better-than-expected quarterly earnings triggered strong buying activity, pushing the stock close to its 52-week high during intraday trade.

Share Price Snapshot

Particular	Value
Current Share Price	₹1,700
Intraday Gain	Around 19%
Day High	₹1,713.70
Day Low	₹1,520
Market Capitalisation	₹3,977 crore
52-Week Range	₹976 – ₹1,714

The rally lifted Tatva Chintan Pharma Chem shares to an intraday high of ₹1,713.70, just below the stock's 52-week high, as investors reacted positively to the company's earnings and expansion plans.

Board Approves Reappointment of Key Directors

Alongside the quarterly results, the board approved the reappointment of Managing Director Chintan Nitinkumar Shah and Whole-time Directors Ajaykumar Mansukhlal Patel and Shekhar Rasiklal Somani for another three-year term.

The reappointments remain subject to shareholder approval at the company's upcoming Annual General Meeting (AGM). The decision provides continuity in leadership as the company undertakes its next phase of manufacturing expansion and product development.

Company Announces ₹200 Crore Dahej Expansion

Tatva Chintan Pharma Chem also approved a ₹200 crore capital expenditure to expand its Dahej-III greenfield manufacturing facility in Gujarat.

The project will add 344 kilolitres (KL) of additional reactor capacity and will be funded through a combination of internal accruals and debt. According to the company, the expansion is expected to be completed within 18–21 months.

Dahej Expansion Details

Particular	Details
Location	Dahej-III, Gujarat
Investment	₹200 crore
Additional Reactor Capacity	344 KL
Funding	Internal Accruals + Debt
Expected Commissioning	18–21 Months

The additional capacity is expected to increase manufacturing flexibility, support commercialisation of new specialty chemicals and improve the company's ability to meet rising customer demand across multiple end-user industries.

Deven Choksey Maintains 'Accumulate' Rating

Following the June quarter results, Deven Choksey Research maintained its 'Accumulate' recommendation on Tatva Chintan Pharma Chem with a target price of ₹1,765, implying an upside of around 8% from prevailing market levels.

Brokerage View

Parameter	Outlook
Rating	Accumulate
Target Price	₹1,765
Expected Upside	Around 8%

According to the brokerage, improving demand across specialty chemicals, higher capacity utilisation and the company's ability to pass on higher raw material costs are expected to support profitability. It also expects EBITDA margins to gradually improve towards the 20%–22% range as operating leverage strengthens.

Growth Drivers Identified by the Brokerage

Deven Choksey Research highlighted multiple growth opportunities that could support Tatva Chintan Pharma Chem's earnings over the medium term.

The brokerage expects demand to remain healthy across pharmaceutical intermediates, specialty chemicals, electrolyte salts, battery chemicals, semiconductor chemicals and continuous flow chemistry solutions. It believes these product categories will remain important contributors to future revenue growth.

According to the brokerage, the proposed Dahej expansion has the potential to generate nearly ₹300 crore in peak annual revenue once fully operational, providing additional manufacturing capacity before the existing facility reaches its utilisation limits.

The brokerage projects a revenue CAGR of around 28%, EBITDA CAGR of approximately 40% and PAT CAGR of nearly 47% during FY26–FY28, supported by capacity additions, new product commercialisation and improving operating leverage.

Company Overview

Tatva Chintan Pharma Chem Ltd is an Indian specialty chemicals manufacturer catering to pharmaceutical, agrochemical, petrochemical, energy storage and advanced material industries. The company manufactures specialty intermediates, phase transfer catalysts, structure directing agents, electrolyte salts and other high-value specialty chemicals for domestic and international customers.

Core Business Segments

Business Segment	Key Products
Pharmaceutical & Agrochemical Intermediates	Specialty intermediates, Glymes
Phase Transfer Catalysts (PTC)	Specialty catalysts
Structure Directing Agents (SDA)	Zeolite manufacturing chemicals
Electrolyte Salts	Battery and energy storage chemicals

Its diversified product portfolio and increasing focus on advanced specialty chemicals have enabled the company to expand into emerging sectors, including electric vehicle batteries, semiconductors and high-performance industrial applications.

The company's latest quarterly performance, ₹200 crore expansion plan and continued investment in specialty chemical manufacturing remain the key developments investors are likely to monitor over the coming quarters, alongside progress on the Dahej project, margin trends and commercialisation of new products.

1. Why did Tatva Chintan Pharma Chem shares rise nearly 19%?

Tatva Chintan Pharma Chem shares surged after the company reported strong Q1 FY27 results. Revenue increased 43% year-on-year to ₹167 crore, net profit more than doubled to ₹16 crore and EBITDA rose 86.6%. The company also announced a ₹200 crore capacity expansion and received a positive brokerage outlook.

2. What were Tatva Chintan Pharma Chem's Q1 FY27 financial results?

For Q1 FY27, Tatva Chintan Pharma Chem reported revenue of ₹167 crore, net profit of ₹16 crore and EBITDA of ₹32.1 crore. EBITDA margin improved to 19.2%, compared with 14.7% in the corresponding quarter of the previous financial year.

3. What is the company's ₹200 crore expansion project?

Tatva Chintan Pharma Chem plans to invest ₹200 crore to expand its Dahej-III manufacturing facility in Gujarat. The project will add 344 KL of reactor capacity and is expected to be commissioned within 18–21 months through funding from internal accruals and debt.

4. What is Deven Choksey Research's target price for Tatva Chintan Pharma Chem?

Deven Choksey Research has maintained an 'Accumulate' rating on Tatva Chintan Pharma Chem with a target price of ₹1,765. The brokerage expects the company's capacity expansion, improving margins and growing demand for specialty chemicals to support earnings growth over the medium term.

5. What businesses does Tatva Chintan Pharma Chem operate in?

Tatva Chintan Pharma Chem manufactures specialty chemicals used across pharmaceuticals, agrochemicals, petrochemicals, energy storage and advanced materials. Its key product portfolio includes pharmaceutical intermediates, phase transfer catalysts, structure directing agents and electrolyte salts used in battery applications.